Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy and the combination of nivolumab and ipilimumab (Yervoy) in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer (CRC).

свернуть